| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43,2 M € | -5.9% | 45,9 M € | +21.7% | 37,7 M € | +0.9% | 37,4 M € | +10.7% | 33,8 M € | -21.5% | 43,1 M € | +16.7% | 36,9 M € | +20.9% | 30,5 M € | +8.4% | 28,2 M € | -7.1% | 30,3 M € | +12.4% | 27,0 M € | +6.3% | 25,4 M € | +3.9% | 24,4 M € | +12.8% | 21,6 M € | +33.1% | 16,3 M € | -3.0% | 16,8 M € | +3.5% | 16,2 M € | +7.5% | 15,1 M € | |
| EBITDA | 6,5 M € | -5.3% | 6,9 M € | +1506.5% | 429,0 k € | -83.8% | 2,6 M € | +14.2% | 2,3 M € | -48.6% | 4,5 M € | +107.3% | 2,2 M € | +94.1% | 1,1 M € | -29.2% | 1,6 M € | -50.9% | 3,2 M € | +30.4% | 2,5 M € | +6.7% | 2,3 M € | -11.7% | 2,6 M € | -7.5% | 2,8 M € | +37.6% | 2,1 M € | +10.1% | 1,9 M € | -2.9% | 1,9 M € | +8.8% | 1,8 M € | |
| Operating profit | 3,2 M € | -8.4% | 3,5 M € | +225.9% | -2,8 M € | -651.8% | -370,5 k € | -86.1% | -199,2 k € | -108.3% | 2,4 M € | +1123.1% | 196,7 k € | +120.9% | -942,3 k € | -3228.0% | 30,1 k € | -98.2% | 1,7 M € | +37.9% | 1,2 M € | +16.0% | 1,1 M € | -6.7% | 1,1 M € | -30.2% | 1,6 M € | +143.3% | 667,4 k € | +82.2% | 366,3 k € | +25.5% | 291,9 k € | -59.3% | 716,4 k € | |
| Profit/loss | 2,8 M € | +4.2% | 2,7 M € | +180.1% | -3,4 M € | -353.4% | -745,0 k € | -29.4% | -575,6 k € | -130.7% | 1,9 M € | +5659.4% | 32,5 k € | +102.2% | -1,5 M € | -287.2% | -378,2 k € | -138.0% | 995,1 k € | +249.5% | 284,7 k € | +29.4% | 220,0 k € | -29.2% | 310,7 k € | -50.3% | 624,7 k € | +131.4% | 270,0 k € | +130.1% | 117,3 k € | +454.0% | -33,1 k € | -109.4% | 353,5 k € | |
| Equity | 19,4 M € | +16.1% | 16,7 M € | +49.8% | 11,1 M € | +36.3% | 8,2 M € | -9.4% | 9,0 M € | -2.0% | 9,2 M € | +24.7% | 7,4 M € | -0.3% | 7,4 M € | -17.0% | 8,9 M € | -4.9% | 9,4 M € | +19.9% | 7,8 M € | +3.8% | 7,5 M € | +3.0% | 7,3 M € | +4.4% | 7,0 M € | +9.8% | 6,4 M € | +4.4% | 6,1 M € | +1.9% | 6,0 M € | -0.7% | 6,0 M € | |
| Total assets | 34,3 M € | -5.1% | 36,1 M € | +16.8% | 31,0 M € | +15.4% | 26,8 M € | +4.1% | 25,8 M € | +0.3% | 25,7 M € | +14.3% | 22,5 M € | -6.5% | 24,0 M € | -7.5% | 26,0 M € | +31.1% | 19,8 M € | +11.2% | 17,8 M € | -0.4% | 17,9 M € | -4.2% | 18,7 M € | +23.5% | 15,1 M € | +8.4% | 14,0 M € | -5.4% | 14,8 M € | -1.7% | 15,0 M € | -12.6% | 17,2 M € | |
| Cash | 173,3 k € | +250.1% | 49,5 k € | -22.2% | 63,6 k € | +2.6% | 62,0 k € | -77.5% | 275,7 k € | -91.1% | 3,1 M € | +947.7% | 294,8 k € | +25.2% | 235,4 k € | -74.2% | 913,5 k € | -46.3% | 1,7 M € | +27.3% | 1,3 M € | +3.6% | 1,3 M € | +235.9% | 383,6 k € | -75.4% | 1,6 M € | +295.3% | 394,8 k € | -62.9% | 1,1 M € | +1093.9% | 89,1 k € | -86.4% | 656,1 k € | |
| Debts | 13,1 M € | -26.4% | 17,8 M € | -1.5% | 18,1 M € | +3.7% | 17,5 M € | +11.0% | 15,7 M € | -1.1% | 15,9 M € | +5.7% | 15,0 M € | -8.0% | 16,3 M € | -3.5% | 16,9 M € | +69.1% | 10,0 M € | +3.3% | 9,7 M € | -3.4% | 10,0 M € | -10.6% | 11,2 M € | +38.4% | 8,1 M € | +7.3% | 7,6 M € | -12.4% | 8,6 M € | -4.0% | 9,0 M € | -18.8% | 11,1 M € | |
| Staff | 182,6 | 181,2 | 188,7 | 190,7 | 186 | 187,6 | 168,3 | 158,1 | 158,7 | 144,3 | 142,2 | 133,7 | 125,7 | 116,4 | 103,7 | 97,5 | 93,4 | 85,3 | ||||||||||||||||||
Public limited company · Puurs-Sint-Amands · incorporated on 04/04/1986 · 182,6 ETP
Public limited company profitable and well capitalised. Cash position rising (+250.1%).
Solid counterparty for a standard engagement.
Purna Pharmaceuticals is a Public limited company incorporated in 1986. Its main activity is: Manufacture of pharmaceutical preparations. Its registered office is in Puurs-Sint-Amands. It employs on average 182,6 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette